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Hulsbergen-van de Kaac, Lambertus A.L.M. Kiemeneyb,d, R. Alexandra
Goldbohme, Jack A. Schalkenb and Piet A. van den Brandta
Objectives Hypertension and/or antihypertensive
medication are reported to be risk factors of renal cell
carcinoma (RCC). We investigated whether these risk
factors are associated with von Hippel-Lindau gene (VHL)
mutations in RCC.
Methods The Netherlands Cohort Study on Diet and
Cancer (NLCS) started in 1986 (n U 120 852 men and
women) and uses the case–cohort methodology. After
11.3 years of follow-up, 337 RCC cases and 4774 subcohort
members were available for analysis. DNA was
isolated from paraffin-embedded tumour tissue
for VHL analysis.
Results Cohort members who reported hypertension
or use of antihypertensive medication had a slightly
(non-significant) increased risk of RCC: rate ratios
(RR) 1.22 [95% confidence interval (CI), 0.94–1.58] and 1.14
(95% CI, 0.85–1.52), respectively. RRs were adjusted for
sex, age, body mass index (BMI) and cigarette smoking. Of
the 235 patients for whom tumour tissue specimens were
collected, 187 had a clear-cell RCC, of whom 114 had a VHL
mutation. History of hypertension was associated with a
non-significantly increased risk of clear-cell RCC with VHL
mutations: RR U 1.34 (95% CI, 0.87–2.07), and was not
associated with the risk of clear-cell RCC without VHL
mutations; RR U 0.88 (95% CI, 0.51–1.53). Use of diuretics
was associated with clear-cell RCC without VHL mutations;
RRU 2.11 (95% CI, 1.16–3.83).
Conclusions In this study non-significantly increased risks
for history of hypertension and use of antihypertensive
medication with RCC were observed. The association with
hypertension was stronger in RCC patients with VHL
mutations, while there was a positive association of
diuretics use and risk of RCC without VHL mutations.
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Introduction
Hypertension and use of diuretics or other antihyperten-
sive medication have been found to be risk factors for
renal cell carcinoma (RCC) in many epidemiological
studies [1,2]. It is unclear, however, whether the in-
creased risk is caused by hypertension itself, or by the
use of antihypertensive medication. Some recent studies
showed that diuretic medication was no longer a risk
factor after controlling for the diagnosis of hypertension
[3,4], suggesting that not medication but hypertension is
a risk factor for RCC. Several prospective studies have
studied the effect of hypertension on the risk of RCC
[5–12], but few prospective cohort studies were also
able to study the use of antihypertensive medication
[8,11,12].
RCC is classified in different subtypes. The majority of
RCC are of the clear-cell type (80%); other subtypes are
papillary RCC (10%), chromophobe RCC (5%), collect-
ing-duct carcinoma (1%) and unclassified RCC (3–5%)
[13]. Von Hippel–Lindau disease (VHL) is a rare inher-
ited disorder associated with (amongst others) an increa-
sed risk for clear-cell RCC [14]. After the identification
of the VHL gene on chromosome 3p25, it became evi-
dent that this gene is also involved in the development
of sporadic clear-cell RCC. It is estimated that
Original article 1997
0263-6352  2005 Lippincott Williams & Wilkins
approximately 75% of all sporadic clear-cell RCCs har-
bour bi-allelic VHL defects [15]. Two studies suggested
that risk factors, such as occupational exposure to tri-
chloroethylene and fruit consumption, are associated
with mutations in the VHL gene in RCC [16,17].
Despite the fact that many studies have observed an
association between the diagnosis of hypertension and/or
use of antihypertensive medication and RCC risk, there
is still much uncertainty with respect to the biological
mechanism. Gago-Dominguez [18] suggested the ‘lipid
peroxidation’ hypothesis as the underlying mechanism,
but this remains to be proven. The different subtypes of
RCC may have different aetiologies. The VHL gene is the
main causative gene for sporadic clear-cell RCC [15].
Whether hypertension and/or use of antihypertensive
medication are associated with clear-cell RCC, or more
specifically with mutational status of the VHL gene, has
not been investigated before. It is conceivable that these
risk factors are associated with specific subtypes of RCC,
or with mutational status of the VHL gene in clear-cell
RCC.
We decided to study whether hypertension and use of
antihypertensive medication were associated with risk of
RCC, and more specifically with mutational status of the
VHL gene in clear-cell RCC, within a large prospective
cohort study.
Materials and methods
Subjects
The Netherlands Cohort Study on diet and cancer is a
prospective cohort study, which started in September
1986. The study design has been reported in detail
elsewhere [19]. Briefly, the cohort included 120 852
men and women, aged 55–69 years, at the beginning
of the study. The study was designed as a case–cohort
study, using all cases and a random sample of 5000
persons from the cohort (subcohort), who have been
followed to estimate the accumulated person-years in
the entire cohort [20]. Follow-up for incident cancer
has been established by computerized record linkage
with the Netherlands Cancer Registry (NCR) and
PALGA, a national database of pathology reports. The
method of record linkage to obtain information on cancer
incidence has been described previously [21]. The com-
pleteness of cancer follow-up was estimated to be more
than 96% [22]. From 1986 to 1997 (11.3 years follow-up)
355 kidney cancer cases [International Classification of
Diseases for Oncology, version 3 (ICD-O-3): C64.9] were
identified. Urothelial cell carcinomas were excluded and
only histologically confirmed epithelial cancers were
included (ICD-O: M8010-8119, 8140-8570), leaving
337 cases. All subcohort members who reported prevalent
cancer (excluding skin cancer) at baseline were excluded
from analyses (leaving 4774 subcohort members).
VHL mutation analysis
Paraffin blocks of tumours were collected from 51 path-
ology laboratories, the procedures have been described
in detail elsewhere [23]. We were able to collect mater-
ial for 251 cases. One experienced pathologist (C.A.H.K.)
revised all haematoxylin and eosin (HE)-stained slides.
The RCCs were classified according to the World Health
Organization (WHO) Classification of Tumours, 2002
[24]. The protocol for DNA isolation and mutation ana-
lyses have been described previously [23]. Briefly, par-
affin was removed with xylene and tumour DNA was
extracted by salt precipitation. The entire gene was
amplified using six primer sets, as described before
[23]. Samples were first subjected to polymerase chain
reaction–single-strand conformational polymorphism
(PCR-SSCP) analysis, which was followed by direct sequ-
encing in the case of aberrant or unclear results. Muta-
tions were identified by visual inspection of sequences
provided by the ABI basecaller (Applied Biosystems,
Nieuwerkerk a.d. IJssel, The Netherlands). After revi-
sion and VHL gene mutation analyses, data were available
for 235 cases [23].
Questionnaire
At baseline, all cohort members completed a mailed, self-
administered questionnaire on dietary habits and other
risk factors for cancer [25]. Participants were asked to
report whether a physician had ever diagnosed ‘high
blood pressure’ and at what age the diagnosis was made
(in 5-year age groups from ‘younger than 30 years’, 30–34
years’ to ‘65–69 years’). Duration since diagnosis was
calculated by subtracting the midpoint age in the age
group of diagnosis from the age at baseline and was
categorized into three broad categories: 0–9 years, 10–
19 years and 20 years.
Participants were also asked to report on use of any drugs
that they used longer than 6 months, for what condition
and in what calendar period. All drugs were classified into
therapeutic groups using the Anatomical Therapeutic
Chemical (ATC) classification of the WHO Collaborative
Centre for Drug Statistical Methodology [26,27].
Data analysis
Differences between cases with and without collected
tumour material were assessed by calculating Student
t-tests and chi-squared tests. RRs for RCC were calcu-
lated for history of hypertension and use of antihyper-
tensive medication. Case groups were defined as follows:
total RCC (all histologically confirmed cases of RCC
detected by linkage to cancer and pathology registries;
n ¼ 337); clear-cell RCC (classified as clear-cell RCC
after pathological revision; n ¼ 187); mutated clear-cell
RCC (clear-cell RCC with a mutation in the VHL gene;
n ¼ 114) and wild-type clear-cell RCC (clear-cell RCC
without a mutation in the VHL gene; n ¼ 73). Confoun-
ders considered were age at baseline (years), sex, current
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cigarette smoking (yes/no), cigarettes smoked (number/
day), years of cigarette smoking (years), alcohol consump-
tion (g/day), body mass index (BMI; kg/m2), a history of
diabetes mellitus (yes/no), a history of RCC in first-grade
family (yes/no), non-occupational physical activity (<30,
30–60, 60–90, >90 min/day), occupational physical
activity for men only (<8, 8–12, >8 kJ/min) and socio-
economic status (SES) based on education. Those vari-
ables that were associated with diagnosis of hypertension
(and/or use of antihypertensive medication), that were an
independent risk factor of RCC and that changed the risk
estimates for the association of hypertension (and/or the
use of antihypertensive medication) and RCC more than
10% were included as confounders in multivariable
analyses. Using these criteria, confounders entered in
the analyses were age, sex, BMI, current cigarette smok-
ing, number of cigarettes smoked per day, and number of
years of cigarette smoking.
RRs and corresponding 95% confidence intervals (CI) for
RCC were estimated using Cox proportional hazard
models processed with the STATA statistical software
package (STATA statistical software, Release 7; STATA
Corporation, College Station, Texas, USA; 2001), after
testing the proportional hazards assumption using scaled
Schoenfeld residuals [28]. Standard errors were estimated
using the robust Huber–White sandwich estimator to
account for additional variance introduced by sampling
person-time from the cohort [29]. To obtain P values for
dose–response trends, ordinal exposure variables were
fitted as continuous terms.
Results
Hypertension was reported somewhat more frequently
among RCC cases than among subcohort members
(29.4 versus 26.3%; Table 1). RCC cases also reported
a slightly higher use of antihypertensive medication than
Hypertension and VHL-mutations in RCC Schouten et al. 1999
Table 1 Description of exposure variables and potential confounders in subcohort members (NU 4774), RCC cases (NU 337) and RCC
cases with tissue blocks collected (N U 235), The Netherlands Cohort Study on Diet and Cancer (NLCS) 1986–1997
Subcohort members
(N ¼ 4774) n (%)
RCC cases
(N ¼ 337) n (%)
RCC cases with collected tumour
material (N ¼ 235) n (%)
Hypertension and use of antihypertensive medication
Diagnosis of hypertension
No 3517 (73.7) 238 (70.6) 166 (70.6)
Yes 1257 (26.3) 99 (29.4) 69 (29.4)
Duration since diagnosisa,b
0–9 years 664 (53.7) 56 (57.7) 35 (51.5)
10–19 years 367 (29.7) 27 (27.8) 24 (35.3)
20þ years 206 (16.7) 14 (14.4) 9 (13.2)
Ever use of hypertension medication
No 3767 (78.9) 259 (76.9) 172 (73.2)
Yes 1007 (21.1) 78 (23.2) 63 (26.8)
Ever use of diuretics
No 4238 (88.8) 298 (88.4) 206 (87.7)
Yes 536 (11.2) 39 (11.6) 29 (12.3)
Ever use of beta-blockers
No 4203 (88.0) 287 (85.2) 195 (83.0)
Yes 571 (12.0) 50 (14.8) 40 (17.0)
Potentially confounding variables
Age at baseline (years)c 61.4 (4.2) 61.9 (3.9) 62.0 (3.9)
BMI (kg/m2)c 25.1 (3.1) 25.5 (3.0) 25.5 (2.9)
Current cigarette smokingb
No 3397 (71.3) 213 (63.4) 155 (66.0)
Yes 1365 (28.7) 123 (36.6) 80 (34.0)
Number of cigarettes/dayc,d 15.2 (10.2) 17.9 (12.3) 18.3 (12.4)
Years of smokingc,d 31.9 (12.3) 34.2 (12.2) 33.7 (12.1)
Alcohol consumption (g/day)c 10.4 (14.4) 11.5 (14.6) 10.6 (14.0)
Diagnosis of diabetes mellitus
No 4588 (96.1) 326 (96.7) 226 (96.2)
Yes 186 (3.9) 11 (3.3) 9 (3.8)
Family history of RCC
No 4716 (99.0) 332 (98.8) 232 (98.7)
Yes 47 (1.0) 4 (1.2) 3 (1.3)
Non-occupational physical activityb
<30 min/day 1083 (23.2) 73 (22.1) 54 (23.4)
30–<60 min/day 1447 (30.9) 100 (30.2) 67 (29.0)
60–<90 min/day 939 (20.1) 63 (19.0) 47 (20.4)
90 min/day 1210 (25.9) 95 (28.7) 63 (27.3)
Social economic statusb
Primary school 1476 (31.0) 94 (28.0) 64 (27.2)
Lower vocational school 1036 (21.8) 78 (23.2) 57 (24.3)
Intermediate vocational school 1584 (33.3) 109 (32.4) 74 (31.5)
Higher vocational school or university 613 (12.9) 51 (15.2) 36 (15.3)
RCC, renal cell carcinoma; BMI, body mass index. aOnly for persons who reported a diagnosis of hypertension. bDue to missing values totals do not add up to 4774, 337
and 235, respectively. cMean (standard deviation). dOnly for ever-smokers.
the subcohort members (23.2 versus 21.1%). RCC cases
had a higher BMI, were more often current cigarette
smokers and had been diagnosed less frequently with
diabetes mellitus than subcohort members. When these
variables were compared between patients with tumour
material and patients without tumour material, no sig-
nificant differences were observed. Only the percentage
of antihypertensive medication use was significantly
higher for cases with tumour tissue collected compared
to cases for whom no tissue could be collected (P ¼ 0.02).
Cohort members who reported a history of hypertension
or use of antihypertensive medication at baseline, had a
slightly increased risk of RCC: rate ratio (RR) 1.22 [95%
confidence interval (95% CI), 0.94–1.58] and 1.14 (95%
CI, 0.85–1.52), respectively (Table 2). These RRs (as all
following RRs) were adjusted for sex, age, BMI, and
cigarette smoking. There was no difference between
men and women with respect to the association between
history of hypertension and RCC risk (P for inter-
action ¼ 0.99). A diagnosis of hypertension was associa-
ted with a RR of 1.21 (95% CI, 0.87–1.69) in men and a
RR of 1.21 (95% CI, 0.80–1.84) in women. The RR for
use of antihypertensive medication was also nearly the
same in men and women (P for interaction ¼ 0.92). With
an increasing time interval between diagnosis of hyper-
tension and baseline, hypertension was associated with
slightly decreasing risks of RCC, with RRs of 1.27; 1.16
and 1.15, for time intervals of less than 10 years, 10–19
years, and 20 years or more, respectively.
Studying the interaction of the diagnosis of hypertension
and antihypertensive medication use did not reveal diver-
gent results. The RRs for use of diuretics or beta-blockers
in cohort members, who had not reported a diagnosis
of hypertension, were relatively high, but the number of
cases and person-years in the subcohort was small
(Table 2).
Repeated analysis with exclusion of the first 2 years of
follow-up did not alter the results considerably: RRs were
slightly lower (data not shown).
Of the 235 patients for whom tissue specimens were
available, 187 had a clear-cell RCC (80%). In 114 patients
with clear-cell RCC a mutation in the VHL gene was
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Table 2 Age-adjusted and multivariable-adjusted rate ratios (RR) for total RCC (N U 337) according to hypertension and antihypertensive
medication use; The Netherlands Cohort Study on Diet and Cancer (NLCS) 1986–1997
Variable
Age- and sex-adjusted analyses Multivariable-adjusted analyses
n cases/person-years subcohort RRa 95% CI n cases/person-years subcohort RRb 95% CI
Diagnosis of hypertension
No 238/36943 1 Ref 210/33554 1 Ref
Yes 99/13054 1.24 0.97–1.59 90/12097 1.22 0.94–1.58
Time interval between diagnosis of hypertension and baseline
No diagnosis of hypertension 238/36943 1 Ref 210/33554 1 Ref
0–9 years 56/6918 1.32 0.97–1.79 51/6365 1.27 0.92–1.76
10–19 years 27/3753 1.16 0.77–1.76 24/3459 1.16 0.74–1.81
20þ years 14/2181 1.06 0.61–1.86 14/2075 1.15 0.66–2.03
P for trend 0.44 0.71
Antihypertensive medication use
No 259/39787 1 Ref 231/36237 1 Ref
Yes 78/10210 1.20 0.92–1.56 69/9415 1.14 0.85–1.52
Diuretic use
No 298/44553 1 Ref 265/40649 1 Ref
Yes 39/5444 1.16 0.82–1.64 35/5003 1.14 0.79–1.66
Beta-blocker use
No 287/44157 1 Ref 255/40256 1 Ref
Yes 50/5839 1.30 0.94–1.78 45/5394 1.27 0.90–1.78
Diagnosis of hypertension (Hyp) and antihypertensive medication use (Med)
No Hyp/No Med 219/34310 1 Ref 194/31148 1 Ref
No Hyp/Yes Med 19/2633 1.06 0.65–1.73 16/2408 0.95 0.56–1.64
Yes Hyp/No Med 40/5478 1.19 0.83–1.68 37/5090 1.16 0.80–1.68
Yes Hyp/Yes Med 59/7576 1.29 0.95–1.75 53/7008 1.25 0.91–1.74
Diagnosis of hypertension (Hyp)and diuretic use (Med)
No Hyp/No Med 230/36155 1 Ref 203/32837 1 Ref
No Hyp/Yes Med 8/788 1.69 0.80–3.57 7/717 1.54 0.68–3.46
Yes Hyp/No Med 68/8398 1.32 0.99–1.75 62/7812 1.28 0.95–1.73
Yes Hyp/Yes Med 31/4657 1.15 0.77–1.69 28/4286 1.15 0.76–1.75
Diagnosis of hypertension (Hyp) and beta-blocker use (Med)
No Hyp/No Med 222/35348 1 Ref 196/32098 1 Ref
No Hyp/Yes Med 16/1595 1.41 0.82–2.41 14/1456 1.36 0.76–2.44
Yes Hyp/No Med 65/8811 1.23 0.92–1.64 59/8159 1.21 0.89–1.64
Yes Hyp/Yes Med 34/4243 1.33 0.91–1.95 31/3939 1.31 0.87–1.96
RCC, renal cell carcinoma; RR, rate ratio; CI, confidence interval; Ref, reference. aRate ratio adjusted for age (years) and sex. bRate ratio adjusted for age (years), sex, body
mass index (kg/m2), current cigarette smoking at baseline (yes versus no), number of cigarettes smoked per day (continuous) and years of cigarette smoking (continuous).
detected (61%). The RR for diagnosis of hypertension
was higher in cases with a VHL mutation than in cases
with VHL wild type: RRs 1.34 (95% CI, 0.87–2.07) and
0.88 (95% CI, 0.51–1.53), respectively (Table 3). By
contrast, the RR for use of antihypertensive medication
was higher in cases with VHL wild type: RR ¼ 1.53 (95%
CI, 0.89–2.61). The RR for use of diuretics was statisti-
cally significantly increased in cases with VHL wild type,
RR ¼ 2.11 (95% CI, 1.16–3.83).
The RR was also increased in cohort members who used
diuretics or beta-blockers and did not report a diagnosis of
hypertension but, as in total RCC, numbers of cases and
subcohort person-years were very small and the confi-
dence intervals were wide.
Discussion
In this study we observed that hypertension and use of
anti-hypertensive medication were associated with a
slightly increased, although statistically non-significant,
risk of RCC. The association with hypertension was
stronger in RCC patients with VHL mutations, while
the association with use of antihypertensive medication
was stronger in cases with VHL wild type. Diuretics were
associated with an increased risk of clear-cell RCC with
VHL wild type.
These results from the Netherlands Cohort Study on
Diet and Cancer are most likely not affected by selection
or information bias. Selection bias is unlikely given the
high level of follow-up in terms of cases and subcohort
person-years [22,30]. In theory, selection bias may have
occurred in the collection of tissue samples [31]. For 235
of the 337 cases (70%), tumour material could be col-
lected. There was no indication for bias in the selection of
cases with tumour material according to the risk factors
and potential confounders studied, except for the use of
antihypertensive medication, which can be attributed
most likely to chance. Information bias is unlikely in
our study because the information with respect to the risk
factors was collected before the diagnosis of RCC. Diag-
nosis of hypertension and use of antihypertensive medi-
cation were self-reported, however, and misclassification
of exposure is a potential source of bias. In two studies
conducted in the USA moderate agreement between
self-report and actual measurement of blood pressure
was observed; estimates of sensitivity for self-reported
hypertension were between 62 and 82% [32] and 71% in
the NHANES III study [33]. In an American validation
study, sensitivity of recall for use of antihypertensive
medication among controls was 86% after 2 years and
79% after 8 years [34]. In a small validation study (207
subjects) within our cohort study, use of medication for
the cardiovascular system was recalled correctly by 66%
of the users [26]. The subgroup of cases and subcohort
members that reported use of antihypertensive medi-
cation, without reporting a diagnosis of hypertension,
may indicate misclassification. Examining the indications
for medication reported by the participants in the ques-
tionnaire at baseline revealed that only 11% of the
persons in this group reported that the medication was
used because of hypertension, suggesting that misclassi-
fication is limited. The misclassification of self-reported
hypertension and use of antihypertensive medication is
expected to be non-differential, attenuating the rate
ratios towards one.
In a meta-analysis [2] based on 13 case–control studies, a
pooled adjusted odds ratio of 1.75 (95% CI, 1.61–1.90)
was calculated for the association between hypertension
and RCC. This pooled odds ratio did not include results
from prospective cohort studies. Four prospective cohort
studies measured blood pressure at baseline and followed
the cohort members for the occurrence of RCC [5,6,9,10].
All studies found increased risks of RCC with increasing
blood pressure. The outcomes of these studies are diffi-
cult to compare with our study, because of the different
exposure measurement. Three prospective cohort stu-
dies used self-reported diagnosis of hypertension to
define the exposure [8,11,12] and show therefore the
highest resemblance with our study design. Two of these
studies reported increased RRs for diagnosis of hyper-
tension and RCC risk [11,12]. These studies were rela-
tively small, however, with 14 and 62 RCC cases,
respectively. The Cancer Prevention Study II [8]
included 1.2 million subjects and 335 RCC deaths after
7 years of follow-up. Self-reported diagnosis of hyperten-
sion was associated with RCC deaths in females (RR, 2.2;
95% CI, 1.5–3.2), but not in males (RR, 1.1; 95% CI,
0.9–1.5) [8]. The RRs for hypertension observed in the
current study are lower than the pooled odds ratio for
case–control studies [2], but our estimates point in the
same direction. Also, several other studies have pub-
lished RRs comparable to ours, especially for males
[4,8, 35–37].
In another meta-analysis, a pooled odds ratio was calcula-
ted for use of diuretics and risk of RCC [1]. Based on nine
case–control studies, an average odds ratio was calculated
of 1.55 (95% CI, 1.42–1.71). Some of the included studies
used self-report, while others used medical files or data
from a pharmacy database [4,36,38,39]. Three prospec-
tive cohort studies also showed an increased risk for use of
diuretics, with an exception for males in the Cancer
Prevention Study II [7,8,11].
Hypertension may be a possible cause, but it may also be
an early symptom of RCC [40]. The increased risk of
hypertension may therefore reflect detection bias.
Whether this bias is present may be evaluated by exclud-
ing cases from the analysis that were detected shortly
after baseline measurement, or by investigating the
relative risks according to time interval between diag-
nosis of hypertension and baseline. In our study, relative
Hypertension and VHL-mutations in RCC Schouten et al. 2001
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risks were slightly lower after exclusion of cases in the
first 2 years of follow-up, and duration between diagnosis
of hypertension and baseline was associated with slightly
decreasing risks estimates. In a Danish record-linkage
study [7] a U-shaped pattern was observed, with highest
risks for the shortest and the longest time intervals. Other
studies did not observe a modification of the risk esti-
mates according to time interval [4,10,38,41,42].
Despite the large number of epidemiological studies,
there is little convincing evidence with respect to the
biological mechanism between hypertension or use of
antihypertensive medication and the development of
RCC. Gago-Dominguez et al. [18] suggested that lipid
peroxidation, which is increased in obese and hyperten-
sive individuals, might be responsible – at least in part –
for the increased risk of RCC. By-products of lipid
peroxidation have been shown to react with renal DNA
to form adducts [18]. Diuretic therapy might be carcino-
genic through conversion in the stomach to carcinogenic
nitroso derivates or through a low-grade carcinogenic
effect on the renal tubular cell, its principal target [1].
In our study, we also investigated whether hypertension
and/or use of antihypertensive medication were associ-
ated with mutational status of the VHL gene. The VHL
gene is a tumour suppressor gene. Loss of function is an
early event in most cases of clear-cell RCC, by mutation
or methylation of the promoter region. When hyperten-
sion and/or use of antihypertensive drugs are related to
RCC risk, it is conceivable that these risk factors are
associated with specific subtypes of RCC, e.g. clear-cell
RCC with mutations in the VHL gene. In our analysis
somewhat higher risks were found for hypertension in
relation to the risk of clear-cell RCC with a mutation in
the VHL gene, and slightly decreased risks in cases with
VHL wild type. For use of antihypertensive medication
and especially diuretic treatment, we observed the oppo-
site; RRs were increased in cases with VHL wild type and
only slightly increased in cases with mutations in the VHL
gene. It is possible that diagnosis of hypertension and use
of diuretics and risk of clear-cell RCC work through
different pathways (through a mutation in the VHL gene
or not). However, false-positive findings because of
multiple testing and small numbers cannot be excluded.
This is the first study to evaluate the association of hyper-
tension and/or use of antihypertensive medication with
mutations in the VHL gene. Without a specific a priori
hypothesis it is difficult to exclude chance findings,
especially with the small numbers in the subanalyses.
The findings with respect to the possible association with
the VHL gene need to be confirmed in future studies.
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